IMpower010: Atezo improves DFS in stage II-IIIA NSCLC (HR-0.79, 0.64-.0.96, p-0.02). 👏👏Thrilled to see the presentation! The era of adjuvant ICI in NSCLC officially started.#ASCO2021meetinglibrary.asco.org/record/195950/u2026
Effect of antibiotic therapy on immunotherapy outcomes for non-small cell lung cancer: Analysis from the Veterans Health Administration Database.#ASCO2021 Detrimental effect of antibiotics during ICI- something we should consider. meetinglibrary.asco.org/record/198518/u2026
תגובות אחרונות